Status:
TERMINATED
Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
35-75 years
Phase:
NA
Brief Summary
Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will...
Detailed Description
As in Brief description
Eligibility Criteria
Inclusion
- FEV1 \< 70% predicted at baseline on spirometry
- significant smoking history or alpha 1 antitrypsin deficiency
- no evidence of current infection or restrictive lung disease
Exclusion
- history of other significant respiratory disease
- significant respiratory infection within 6 weeks
- history of significant physical or mental illness rendering them unfit for the study in the opinion of the investigator
- taken part in any other research within the past 12 months, or received exposure to ionizing radiation
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00180843
Start Date
September 1 2005
End Date
February 1 2008
Last Update
September 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Hammersmith Campus
London, London, United Kingdom, W12 0HS